title: The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke.
abstract: The ability of captopril and losartan treatment to restore cerebral blood flow (CBF) autoregulation after intracerebral hemorrhagic stroke (HS) was assessed in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp). Laser Doppler techniques assessed CBF autoregulation in the middle cerebral artery (MCA) perfusion domain and a pressure myograph was used to measure pressure-dependent constriction (PDC) in isolated MCAs before and after stroke and after 13, 33, and 63 days of poststroke captopril or losartan treatment. The treatments did not lower blood pressure (BP) and equally suppressed plasma aldosterone after HS. The HS development was associated with the loss of CBF autoregulation, high CBF, increased CBF conductance to elevations in BP, and the loss of PDC in the MCAs. Both treatments restored these functions to prestroke levels within 13 days. The PDC and CBF autoregulation subsequently deteriorated after 63 days of captopril treatment while being maintained at prestroke levels over all durations of losartan treatment. The SHRsp subjected to 35 days of poststroke losartan treatment exhibited less blood-brain barrier (BBB) disruption and brain herniation than captopril-treated SHRsp. The superior ability of losartan to restore CBF autoregulation and myogenic function may have contributed to the more effective attenuation of cerebral damage after HS.
authors.affiliation: Division of BioMedical Sciences, Memorial University, Health Science Center, St John's, Newfoundland, Canada. jsmeda@mun.ca
authors.forename: John S
authors.initials: JS
authors.lastname: Smeda
authors.forename: Noriko
authors.initials: N
authors.lastname: Daneshtalab
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D001812:Blood-Brain Barrier / Q000502:physiology; D001921:Brain / Q000473:pathology; D002216:Captopril / Q000627:therapeutic use*; D002543:Cerebral Hemorrhage / Q000150:complications* / Q000473:pathology; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004032:Diet; D006706:Homeostasis / Q000187:drug effects*; D019808:Losartan / Q000627:therapeutic use*; D020768:Middle Cerebral Artery / Q000503:physiopathology; D051381:Rats; D011918:Rats, Inbred SHR; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D014661:Vasoconstriction / Q000502:physiology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D019808:Losartan